Global Famitinib Malate Capsules Market Strategic Research Report

Scope of the Report

The global Famitinib Malate Capsules market size is predicted to grow from US$ 10.17 million in 2025 to US$ 41.76 million in 2032; it is expected to grow at a CAGR of 6.5% from 2026 to 2032.

Famitinib malate is an oral multi-target tyrosine kinase inhibitor that mainly acts on various kinase targets such as VEGFR, PDGFR, and c-Kit. It exerts anti-tumor effects by inhibiting tumor angiogenesis and blocking signal transduction for tumor cell proliferation. Formulated as oral capsules in the form of malate salt, it is mainly used clinically for the treatment of advanced or metastatic solid tumors. It is often combined with immune checkpoint inhibitors to improve therapeutic efficacy. Characterized by a broad target spectrum, convenient oral administration, and a wide anti-tumor range, it has clear clinical application value in gynecological tumors, gastrointestinal tumors and other fields.In 2025, global production of Famitinib Malate Capsules reached approximately 1.2 million bottles.

Famitinib malate, a Class 1 innovative drug independently developed by Hengrui Medicine, is the world's first multi-target tyrosine kinase inhibitor approved for the treatment of cervical cancer. Centered on the targeted-immunotherapy regimen in combination with camrelizumab, it fills a key gap in the second-line treatment of recurrent or metastatic cervical cancer. Positioned for patients who have not received bevacizumab, it has formed differentiated competitiveness in the domestic cervical cancer treatment field thanks to its convenient oral administration, broad target coverage and remarkable efficacy. Following its inclusion in the National Reimbursement Drug List at the end of 2025, treatment costs dropped significantly, patient accessibility improved substantially, and clinical penetration accelerated. In the current market landscape, as the only domestically approved targeted-immunotherapy combination regimen for cervical cancer, famitinib competes with imported anti-angiogenic agents, domestic similar TKIs and bispecific antibodies. It holds a core position in second-line treatment by virtue of its medical insurance advantages, local R&D strengths and superior survival benefit data. Meanwhile, its ongoing research covers first-line cervical cancer and other solid tumors, which is expected to further expand its market space and consolidate its leading position in the field of oncology therapy.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Famitinib Malate Capsules market?

What factors are driving Famitinib Malate Capsules market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Famitinib Malate Capsules market opportunities vary by end market size?

How does Famitinib Malate Capsules break out by Type, by Application?

This report presents a comprehensive overview of the global Famitinib Malate Capsules market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 5 mg per capsule
• 10 mg per capsule

Segment by Combination Therapy

• Camrelizumab
• Chemotherapeutic Agents

Segment by Production Technology

• Innovator
• Generic

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Recurrent or Metastatic Cervical Cancer
• Advanced Gastrointestinal Tumors
• Other Advanced Solid Tumors

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Famitinib Malate Capsules market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Recurrent or Metastatic Cervical Cancer, Advanced Gastrointestinal Tumors, Other Advanced Solid Tumors evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact